Pharmaceutical Technology on MSN14h
EC approves Otsuka and Lundbeck’s Rxulti for schizophrenia
The decision was supported by a randomised, six-week, placebo-controlled trial involving 316 adolescent subjects.
Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older
Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in ...
PharmaTimes1d
Rxulti approved in the European Union for adolescent schizophrenia
Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...
The Pharma Letter1d
Rxulti now approved for adolescents in Europe
The European Commission (EC) has approved Danish CNS specialist Lundbeck (LUND: CO) and Otsuka Europe’s Rxulti ...
pharmaphorum4d
Rexulti backed for Alzheimer’s agitation by FDA adcomm
Otsuka and Lundbeck’s antidepressant Rexulti should be approved to treat Alzheimer’s disease-related agitation (AAD), according to FDA advisors – a move that could unlock a sizeable new ...
Fierce Pharma7d
Otsuka debuts new kid-friendly resources about Alzheimer's to ease burden on 'sandwich generation' caregivers
Otsuka America Pharmaceutical is continuing its work to provide support to and advocate for family caregivers. | Otsuka ...
pharmaphorum1d
FDA clears Rexulti as first drug for Alzheimer’s agitation
Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodegenerative disorder.